Clarithromycin stops lung function decline in airway-centered interstitial fibrosis.

Abstract : Airway-centered interstitial fibrosis (ACIF) is a distinct type of lung interstitial fibrosis characterized by lesions centered on the airways. Several cases reported in the literature showed little to no effect of corticosteroids and a high mortality rate in the absence of lung transplantation. No other efficient approach is described for the treatment of this type of fibrosis. We report for the first time the case of a 44-year-old patient diagnosed with ACIF on surgical lung biopsy and stabilized with clarithromycin after failure of systemic corticosteroids. We need to confirm this benefit in other patients to ascertain the anti-inflammatory effect of macrolides, which are far less harmful compared to corticosteroids or immunosuppressant drugs.
Type de document :
Article dans une revue
Respiration, Karger, 2013, 85 (2), pp.156-9. 〈10.1159/000341982〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00872810
Contributeur : Morgane Le Corre <>
Soumis le : lundi 14 octobre 2013 - 14:40:32
Dernière modification le : lundi 26 mars 2018 - 15:28:42

Identifiants

Collections

Citation

Stéphane Jouneau, M. Kerjouan, S. Caulet-Maugendre, S. Guillot, C. Meunier, et al.. Clarithromycin stops lung function decline in airway-centered interstitial fibrosis.. Respiration, Karger, 2013, 85 (2), pp.156-9. 〈10.1159/000341982〉. 〈inserm-00872810〉

Partager

Métriques

Consultations de la notice

464